Potential biomarker found for ALS patients; Daiichi Sankyo exec talks biomarker challenges;

> Serum N-acetylaspartate could be a worthy biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, after it was found in significantly higher volumes in ALS patients. The study was published in the Archives of Neurology. Article

> Santa Clara, CA-based biotech NextBio has discovered a potential cancer biomarker in the so-called "gene desert" in the human genome. Release

> Dr. Catherine Larue has been named the executive vice president of biomarkers at GENFIT. Larue previously worked at Bio-Rad in R&D and business units, as well as the immunology department at Sanofi Diagnostics Pasteur. Announcement

And Finally... Dr. Robert Beckman, the executive director of clinical development oncology at Daiichi Sankyo, discussed the difficulties facing the biomarker market with Hanson Wade: the discussion highlighted that the main issues it faces are maximizing efficiency and managing their resources, whether it's the patient market or their finances. Daiichi Sankyo release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.